This study aimed to compare the risk stratification performance of the TSP-9 test vs benchmarks of generalist and expert pathology.

This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.

This study evaluated the predictive performance of a tissue systems pathology test (TissueCypher, TSP-9) versus current clinicopathologic variables in a multi-center cohort of BE patients.

Study data from Castle Biosciences' collaberation with the National Cancer Institutes SEER program registries.

A risk prediction test identifies patients with non-dysplastic Barrett's esophagus who are at high risk for progression to high-grade dysplasia or cancer.

Cutaneous squamous cell carcinoma (cSCC) has become a significant public health issue due to its rapidly rising incidence and an estimated 1.8 million newly diagnosed cases annually. As with other cancers, treatment decisions for patients with cSCC are based primarily on a patient’s risk for poor outcomes.

The risk prediction assay provided significant risk stratification in BE patients with LGD and identified progressors that the experts downstaged to NDBE.

Independent mulit-center study demonstrates risk-aligned treatment plans guided by DecisionDx-Melanoma lead to better patient outcomes.

DecisionDx-Melanoma test results influenced 85% of clinicians’ decisions regarding the SLNB surgical procedure. Use of the test results could help avoid unnecessary procedures in low-risk patients whose tumor biology indicates they could safely forgo the procedure.

A quantitative, multiplexed biomarker imaging approach termed TissueCypher™ that applies systems biology to anatomic pathology.

Using 31-GEP results to guide clinical management and surveillance based on personalized risk of MSS can direct care, improving patient outcomes.